Related
Soleno Reports Positive Top-line Results from Prader-Willi Study
Rare Daily Staff Soleno Therapeutics reported positive top-line results from the randomized withdrawal period of Study C602, […]
Read moreTakeda Licenses ALS Therapy from AcuraStem for up to $580 Million
Rare Daily Staff Takeda has entered into a license agreement with AcuraStem to develop and commercialize the […]
Read moreIonis Reports Positive Phase 3 Results for FCS Therapy
Ionis Reports Positive Phase 3 Results for FCS Therapy Rare Daily Staff Ionis Pharmaceuticals reported positive topline […]
Read moreAlfasigma to Acquire Intercept, Expanding the Global Footprint in Liver Diseases
Rare Daily Staff Italian pharmaceutical company Alfasigma is acquiring Intercept Pharmaceuticals, which is focused on therapeutics for […]
Read moreNovartis Phase 3 Study of Radioligand Therapy Meets Primary Endpoint in Rare Neuroendocrine Cancer
Rare Daily Staff Novartis said its radioligand therapy Lutathera met its primary endpoint in a phase 3 […]
Read moreBridgeBio Raises $250 Million in a Private Placement Equity Financing
Rare Daily Staff BridgeBio Pharma, a commercial-stage company focused on genetic diseases and cancers, raised $250 million […]
Read moreEuropean Trade Group Warns Proposed Overhaul to Orphan Regulations Decrease Innovation and Hurt Patients
Rare Daily Staff Proposed changes to the European Union’s Orphan Medicinal Product Regulation will reduce investment in […]
Read moreFDA Grants Fast Track Designation for Disc Medicine’s Treatment for Polycythemia Vera
Rare Daily Staff The U.S, Food and Drug Administration has granted Fast Track designation to Disc Medicine’s […]
Read moreTravere Misses Secondary Endpoint in Pivotal Trial Comparing Filspari to Generic in IgA Nephropathy
Rare Daily Staff Travere Therapeutics reported topline two-year, confirmatory, secondary endpoint results from the company’s pivotal, head-to-head […]
Read more